Abstract
The identification that breast cancer is hereditary was first described in the nineteenth century. With the identification of the BRCA1 and BRCA 2 breast/ovarian cancer susceptibility genes in the mid-1990s and the introduction of genetic testing, significant advancements have been made in tailoring surveillance, guiding decisions on medical or surgical risk reduction and cancer treatments for genetic variant carriers. This review discusses various medical and surgical management options for hereditary breast cancers.
Keywords:
genetic variants; hereditary breast cancer; risk reducing surgery.
MeSH terms
-
Antineoplastic Agents / therapeutic use
-
BRCA1 Protein / genetics
-
BRCA2 Protein / genetics
-
Breast Neoplasms / diagnosis
-
Breast Neoplasms / genetics
-
Breast Neoplasms / therapy*
-
Chemoprevention / methods
-
Chemoprevention / standards
-
Female
-
Genetic Predisposition to Disease
-
Genetic Testing / standards
-
Hereditary Breast and Ovarian Cancer Syndrome / diagnosis
-
Hereditary Breast and Ovarian Cancer Syndrome / genetics
-
Hereditary Breast and Ovarian Cancer Syndrome / therapy*
-
Heterozygote
-
Humans
-
Mastectomy / methods
-
Mastectomy / standards*
-
Mutation
-
Practice Guidelines as Topic
-
Prophylactic Surgical Procedures / methods
-
Prophylactic Surgical Procedures / standards*
-
Salpingo-oophorectomy / methods
-
Salpingo-oophorectomy / standards*
Substances
-
Antineoplastic Agents
-
BRCA1 Protein
-
BRCA1 protein, human
-
BRCA2 Protein
-
BRCA2 protein, human